Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.83 - $5.11 $31,715 - $57,267
-11,207 Reduced 29.03%
27,393 $137,000
Q4 2022

Feb 14, 2023

SELL
$3.0 - $15.17 $1.2 Million - $6.05 Million
-398,744 Reduced 91.17%
38,600 $188,000
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $296,007 - $417,082
21,204 Added 5.1%
437,344 $6.31 Million
Q2 2022

Aug 08, 2022

BUY
$8.22 - $15.13 $3.42 Million - $6.3 Million
416,140 New
416,140 $6.3 Million
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $112,581 - $299,414
-17,188 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$15.51 - $29.31 $266,585 - $503,780
17,188 New
17,188 $278,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.